<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775030</url>
  </required_header>
  <id_info>
    <org_study_id>CBD-OCC-APP</org_study_id>
    <nct_id>NCT04775030</nct_id>
  </id_info>
  <brief_title>Methodology for Developing an Occlusal Appliance With CBD Active Carrier</brief_title>
  <acronym>CBD-OCC-APP</acronym>
  <official_title>Methodology for Developing an Occlusal Appliance With CBD Active Carrier</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Silesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the efficacy of the occlusal appliance with active cannabidiol (CBD) molecules&#xD;
      in TMD patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Occlusal appliance therapies are used in TMD patients. In this research the active CBD&#xD;
      molecules will be released from the occlusal appliance during nighttime, in population of&#xD;
      patients suffering from TMD. The effectiveness of the myorelaxation (sEMG of mastcatory&#xD;
      muscles activity) and analgesic effect( VAS analysis) of occlusal appliance with the CBD&#xD;
      molecules will be compared to the traditional acrylic-resin material used so far for occlusal&#xD;
      appliance manufacture. The aim of the research is the evaluation of the innovative material&#xD;
      effectiveness, used for the production of the occlusal appliance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>experimental and control group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of sEMG activity of masseter muscle</measure>
    <time_frame>40 days</time_frame>
    <description>Reduction of sEMG activity of masseter muscle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of pain intensity in VAS</measure>
    <time_frame>40 days</time_frame>
    <description>Reduction of pain intensity in VAS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Temporomandibular Disorder</condition>
  <condition>Myofascial Pain</condition>
  <condition>Cannabis</condition>
  <condition>Electromyography</condition>
  <condition>Occlusal Appliance</condition>
  <condition>CBD</condition>
  <arm_group>
    <arm_group_label>CBD occlusal appliance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBD occlusal appliance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>occlusal appliance</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Traditional material occlusal appliance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD occlusal appliance</intervention_name>
    <description>Occlusal appliance manufactured with CBD molecules released from material to patients oral cavity during sleep time</description>
    <arm_group_label>CBD occlusal appliance</arm_group_label>
    <other_name>CBD OCC APP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acrylic resin occlusal appliance</intervention_name>
    <description>Acrylic resin occlusal appliance during sleep time</description>
    <arm_group_label>occlusal appliance</arm_group_label>
    <other_name>ACRYLIC OCC APP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient agreement to take part in the study&#xD;
&#xD;
          -  RDC/TMD group Ia and Ib&#xD;
&#xD;
          -  Bruxism Index&gt; 3 ( Brux-off polysomnography)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CBD allergy/hypersensitivity/ addiction&#xD;
&#xD;
          -  Therapy with analgesic drugs&#xD;
&#xD;
          -  Therapy with drugs affecting muscle function&#xD;
&#xD;
          -  Fixed or removable dental prosthesis&#xD;
&#xD;
          -  Ongoing orthodontic treatment&#xD;
&#xD;
          -  Other general disorders affecting muscle tension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena Antonowicz, Adiunct</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technical University of Silesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aleksandra Nitecka-Buchta, Adiunct</last_name>
    <phone>601899069</phone>
    <email>aleksandranitecka@poczta.onet.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Baron, Prof</last_name>
    <phone>0048322717217</phone>
    <email>sbaron@sum.edu.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of TMD Silesian Medical University</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Baron, Prof</last_name>
      <phone>0048322717217</phone>
      <email>s.baron@sum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Aleksandra Nitecka-Buchta, D.M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004 Aug;10(4):417-24.</citation>
    <PMID>15327040</PMID>
  </reference>
  <reference>
    <citation>Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014 Apr 29;82(17):1556-63. doi: 10.1212/WNL.0000000000000363. Review.</citation>
    <PMID>24778283</PMID>
  </reference>
  <reference>
    <citation>Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, List T, Svensson P, Gonzalez Y, Lobbezoo F, Michelotti A, Brooks SL, Ceusters W, Drangsholt M, Ettlin D, Gaul C, Goldberg LJ, Haythornthwaite JA, Hollender L, Jensen R, John MT, De Laat A, de Leeuw R, Maixner W, van der Meulen M, Murray GM, Nixdorf DR, Palla S, Petersson A, Pionchon P, Smith B, Visscher CM, Zakrzewska J, Dworkin SF; International RDC/TMD Consortium Network, International association for Dental Research; Orofacial Pain Special Interest Group, International Association for the Study of Pain. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. J Oral Facial Pain Headache. 2014 Winter;28(1):6-27. doi: 10.11607/jop.1151.</citation>
    <PMID>24482784</PMID>
  </reference>
  <reference>
    <citation>Lobbezoo F, Ahlberg J, Raphael KG, Wetselaar P, Glaros AG, Kato T, Santiago V, Winocur E, De Laat A, De Leeuw R, Koyano K, Lavigne GJ, Svensson P, Manfredini D. International consensus on the assessment of bruxism: Report of a work in progress. J Oral Rehabil. 2018 Nov;45(11):837-844. doi: 10.1111/joor.12663. Epub 2018 Jun 21.</citation>
    <PMID>29926505</PMID>
  </reference>
  <reference>
    <citation>Nitecka-Buchta A, Nowak-Wachol A, Wachol K, Walczyńska-Dragon K, Olczyk P, Batoryna O, Kempa W, Baron S. Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD: A Randomized, Double-Blind Trial. J Clin Med. 2019 Nov 6;8(11). pii: E1886. doi: 10.3390/jcm8111886.</citation>
    <PMID>31698733</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Silesia</investigator_affiliation>
    <investigator_full_name>Aleksandra Nitecka-Buchta</investigator_full_name>
    <investigator_title>dr n. med.</investigator_title>
  </responsible_party>
  <keyword>Temporomandibular Disorder</keyword>
  <keyword>Myofascial Pain</keyword>
  <keyword>Cannabis</keyword>
  <keyword>Electromyography</keyword>
  <keyword>Occlusal appliance</keyword>
  <keyword>CBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temporomandibular Joint Disorders</mesh_term>
    <mesh_term>Temporomandibular Joint Dysfunction Syndrome</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

